Alivus Life Sciences Ltd posts PAT of Rs. 136.96 crores in Q3 FY25

Glenmark Life Sciences Ltd has reported Consolidated financial results for the period ended December 31, 2024.

Financial Results (Q3 FY2025) - QoQ Comparison

The company has reported total income of Rs. 652.30 crores during the period ended December 31, 2024 as compared to Rs. 515.412 crores during the period ended September 30, 2024.

The company has posted net profit / (loss) of Rs. 136.960 crores for the period ended December 31, 2024 as against net profit / (loss) of Rs. 95.316 crores for the period ended September 30, 2024.

The company has reported EPS of Rs. 11.14 for the period ended December 31, 2024 as compared to Rs. 7.75 for the period ended September 30, 2024.

Financials	Q3 FY2025	Q2 FY2025	% Change
Total Income	₹ 652.30 crs	₹515.412 crs	26.56%
Net Profit	₹136.960 crs	₹95.316 crs	43.69%
EPS	₹11.14	₹7.75	43.74%

Financial Results (Q3 FY2025) - YoY Comparison

The company has reported total income of Rs. 652.30 crores during the period ended December 31, 2024 as compared to Rs.574.495 crores during the period ended December 31, 2023.

The company has posted net profit / (loss) of Rs.136.960 crores for the period ended December 31, 2024 as against net profit / (loss) of Rs.118.765 crores for the period ended December 31, 2023.

The company has reported EPS of Rs.11.14 for the period ended December 31, 2024 as compared to Rs.9.67 for the period ended December 31, 2023.

Financials	Q3 FY2025	Q3 FY2024	% Change
Total Income	₹ 652.30 crs	₹574.495 crs	13.54%
Net Profit	₹136.960 crs	₹118.765 crs	15.32%
EPS	₹11.14	₹9.67	15.20%

Financial Results (9 Months Ended FY2025) - YoY Comparison

The company has reported total income of Rs.1761.821 crores during the 9 Months period ended December 31, 2024 as compared to Rs.1755.528 crores during the 9 Months period ended December 31, 2023.

The company has posted net profit / (loss) of Rs.343.759 crores for the 9 Months period ended December 31, 2024 as against net profit / (loss) of Rs.372.952 crores for the 9 Months period ended December 31, 2023.

The company has reported EPS of Rs.27.97 for the 9 Months period ended December 31, 2024 as compared to Rs.30.42 for the 9 Months period ended December 31, 2023.

Financials	9 Months Ended FY2025	9 Months Ended FY2024	% Change
Total Income	₹1761.821 crs	₹1755.528 crs	0.36%
Net Profit	₹343.759 crs	₹372.952 crs	-7.83%
EPS	₹27.97	₹30.42	-8.05%

Shares of Glenmark Life Sciences Ltd was last trading in BSE at Rs. 1173.30 as compared to the previous close of Rs. 1122.65. The total number of shares traded during the day was 16678 in over 1915 trades.

The stock hit an intraday high of Rs. 1221.20 and intraday low of 1101.20. The net turnover during the day was Rs. 19381293.00.

Source : Equity Bulls

Keywords

AlivusLifeSciences Q3FY25 9MFY25 Q3FY2025 9MFY2025 ResultUpdate